WO2009010539A3 - Receptor for interleukin-6 (il-6) from macaca fascicularis - Google Patents

Receptor for interleukin-6 (il-6) from macaca fascicularis Download PDF

Info

Publication number
WO2009010539A3
WO2009010539A3 PCT/EP2008/059325 EP2008059325W WO2009010539A3 WO 2009010539 A3 WO2009010539 A3 WO 2009010539A3 EP 2008059325 W EP2008059325 W EP 2008059325W WO 2009010539 A3 WO2009010539 A3 WO 2009010539A3
Authority
WO
WIPO (PCT)
Prior art keywords
fragments
receptor
compounds
interleukin
macaca fascicularis
Prior art date
Application number
PCT/EP2008/059325
Other languages
German (de)
French (fr)
Other versions
WO2009010539A2 (en
Inventor
Els Anna Alice Beirnaert
Keersmaeker Sophie Germaine De
Original Assignee
Ablynx Nv
Els Anna Alice Beirnaert
Keersmaeker Sophie Germaine De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv, Els Anna Alice Beirnaert, Keersmaeker Sophie Germaine De filed Critical Ablynx Nv
Publication of WO2009010539A2 publication Critical patent/WO2009010539A2/en
Publication of WO2009010539A3 publication Critical patent/WO2009010539A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention relates to a protein from cynomolgus monkey (Macaca fascicularis) that functions as a receptor for interleukin-6 ('IL-6'), and to a nucleic acid encoding the same. The present invention further relates to compounds that interact with (as defined herein) said IL-6 receptor protein. Said compounds may be small chemical entities or biological molecules, and may in particular be proteins or polypeptides. More in particular, said compounds may be immunoglobulins or fragments thereof, such as antibodies, antibody fragments (such as Fab' fragments, F(ab')2 fragments and Fv fragments), constructs derived from antibody fragments (such as ScFv fragments and diabodies), or domain antibodies, single domain antibodies, dAb's or Nanobodies. The compounds described herein are preferably cross-reactive with the human IL-6 receptor.
PCT/EP2008/059325 2007-07-19 2008-07-16 Receptor for interleukin-6 (il-6) from macaca fascicularis WO2009010539A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US96112207P 2007-07-19 2007-07-19
US60/961,122 2007-07-19
US6328708P 2008-02-01 2008-02-01
US61/063,287 2008-02-01

Publications (2)

Publication Number Publication Date
WO2009010539A2 WO2009010539A2 (en) 2009-01-22
WO2009010539A3 true WO2009010539A3 (en) 2009-03-05

Family

ID=39769169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/059325 WO2009010539A2 (en) 2007-07-19 2008-07-16 Receptor for interleukin-6 (il-6) from macaca fascicularis

Country Status (1)

Country Link
WO (1) WO2009010539A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5191235B2 (en) 2005-10-21 2013-05-08 中外製薬株式会社 Heart disease treatment
CN101495146B (en) 2006-04-07 2012-10-17 国立大学法人大阪大学 Muscle regeneration promoter
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
MX2009007830A (en) 2007-01-23 2009-10-07 Univ Shinshu Chronic rejection inhibitor.
WO2009095489A2 (en) * 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
CN102256623A (en) 2008-06-05 2011-11-23 独立行政法人国立癌症研究中心 Neuroinvasion inhibitor
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
TWI457134B (en) * 2009-03-19 2014-10-21 Chugai Pharmaceutical Co Ltd Rheumatoid arthritis treatment
US10618964B2 (en) 2009-04-10 2020-04-14 Ablynx N.V. Nanobody against IL-6R
US8748581B2 (en) * 2009-04-10 2014-06-10 Ablynx N.V. Anti-IL-6R polypeptides and pharmaceutical compositions thereof
DK2578231T3 (en) 2010-05-28 2022-12-12 Chugai Pharmaceutical Co Ltd ANTI-TUMOR T-CELL RESPONSE AMPLIFIER
EP2747782B1 (en) 2011-09-23 2018-01-17 Ablynx NV Prolonged inhibition of interleukin-6 mediated signaling
WO2014200018A1 (en) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
AU2015334984A1 (en) 2014-10-21 2017-04-13 Ablynx Nv Treatment of IL-6R related diseases
TW202339800A (en) 2015-02-27 2023-10-16 日商中外製藥股份有限公司 Composition for treating IL-6-related diseases
US10697883B2 (en) 2015-05-19 2020-06-30 National Center Of Neurology And Psychiatry Method for determining application of therapy to multiple sclerosis (MS) patient
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018932A2 (en) * 1998-09-25 2000-04-06 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
WO2005080429A2 (en) * 2004-02-11 2005-09-01 Warner-Lambert Company Llc Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies
WO2008020079A1 (en) * 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018932A2 (en) * 1998-09-25 2000-04-06 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
WO2005080429A2 (en) * 2004-02-11 2005-09-01 Warner-Lambert Company Llc Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies
WO2008020079A1 (en) * 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IMAZEKI I ET AL: "IL-6 FUNCTIONS IN CYNOMOLGUS MONKEYS BLOCKED BY A HUMANIZED ANTIBODY TO HUMAN IL-6 RECEPTOR", INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, ELMSFORD,NY, US, vol. 20, no. 7, 1 July 1998 (1998-07-01), pages 345 - 357, XP001069949, ISSN: 0192-0561 *

Also Published As

Publication number Publication date
WO2009010539A2 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
WO2009010539A3 (en) Receptor for interleukin-6 (il-6) from macaca fascicularis
WO2006061723A3 (en) Human monoclonal antibodies to influenza m2 protein and methods of making and using same
EA201100527A1 (en) BIOLOGICAL PRODUCTS
EP3339322A3 (en) Immunoglobulin single variable domain antibodies with a c-terminal extension for reduced immunogenicity
EP2352523A4 (en) Improved anti-cd19 antibodies
WO2006071441A3 (en) Antibodies directed to gpnmb and uses thereof
TR201901929T4 (en) Antibodies to TGFBeta.
EA201590631A1 (en) ANTIGENSELVATING PROTEINS, ABLE TO CONNECT TYMUS STROMAL LYMPHOPOETHINE
WO2006130458A3 (en) Antibodies directed to cd20 and uses thereof
EP3300739A3 (en) Antibodies and related molecules that bind to 161p2f10b proteins
WO2009136286A3 (en) Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
IL212056A0 (en) Monoclonal antibodies and methods for their use in the detection of cervical disease
WO2006113643A3 (en) High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
CR20120587A (en) MOLECULES OF UNION TO THE ANTIGEN FIXED BY EGFR, VECTORS THAT CODE THEM AND USE OF THE SAME
WO2007070432A3 (en) Binding proteins specific for insulin-like growth factors and uses thereof
NZ587198A (en) Monoclonal antibodies against the rgm a protein and uses thereof
RU2010133547A (en) ANTI-CLDN ANTIBODIES
GEP20115226B (en) P-cadherin antibodies
EP2511301A3 (en) Human antibodies to ERBB2
MX2009013824A (en) Antigen binding proteins that bind par-2.
WO2007136778A3 (en) Fusion proteins, uses thereof and processes for producing same
WO2006117782A3 (en) Recombinant antibodies against cd55 and cd59 and uses thereof
WO2011002968A3 (en) Polypeptides and method of treatment
UA102061C2 (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
WO2010142551A3 (en) Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08775145

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08775145

Country of ref document: EP

Kind code of ref document: A2